Navigation Links
Antibiotic Combo Fights Resistant TB

2 FDA-approved drugs inhibit both normal and virulent strains, study finds

THURSDAY, Feb. 26 (HealthDay News) -- Combination treatment with two FDA-approved drugs shows promise in treating extensively drug-resistant tuberculosis (XDR-TB), a U.S. study shows.

In laboratory tests, researchers at the Albert Einstein College of Medicine and the National Institute of Allergy and Infectious Diseases found that a combination of the drugs clavulanate and meropenem inhibited the growth of 13 XDR-TB strains. The combination treatment was also effective against normal TB. Both drugs are approved in the United States for treating other bacterial infections in adults and children.

The study was published in the Feb. 27 issue of Science.

Current therapy for normal TB requires four antibiotics that must be taken for at least six months. XDR-TB is resistant to at least four of the drugs used to treat TB. The cure rate for patients with XDR-TB is 12 percent to 60 percent.

"If proven in human subjects, the ability to simplify treatment to just two drugs that work against drug-susceptible [TB], multi-drug-resistant [TB] and XDR-TB could help patients better adhere to therapy," study senior author John S. Blanchard, a professor of biochemistry at Einstein, said in a college news release.

"This discovery could be one of the most promising developments in TB research since the discovery of isoniazid -- it is very exciting," William Jacobs, a professor of microbiology and immunology at Einstein and associate director of the Einstein-Montefiore Center for AIDS Research, said in the news release. Isoniazid, the first effective anti-tuberculosis medication, was discovered in the 1950s.

Plans are under way for clinical studies in Korea and in South Africa to determine whether the combination treatment is effective in patients with XDR-TB.

This highly dangerous form of TB is rare in the United States, with only 83 documented cases in the country between 1993 and 2007. However, XDR-TB is emerging as a serious problem in some developing nations.

More information

The U.S. Centers for Disease Control and Prevention has more about XDR-TB.

-- Robert Preidt

SOURCE: Albert Einstein College of Medicine, news release, Feb. 26, 2009

Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. New antibiotic drug combo to speed up treatment of tuberculosis
2. Newer Antibiotic Speeds TB Healing
3. Antibiotics Not Always Best Bet for Battling Childhood Ear Infections
4. Antibiotic Shows Promise as Stroke Treatment
5. Ear infection superbug discovered to be resistant to all pediatric antibiotics
6. Antibiotics May Not Help Mens Chronic Pelvic Pain: Harvard Doctors Discuss Alternatives
7. Study Shows Antibiotic Harms ALS Patients
8. Dragon Sells EPO Business; Focus on Antibiotic Core Business
9. Drug Combo With Antibiotic May Slow MS Progression
10. Antibiotic treatment targets difficult asthma
11. New Report Underscores Need for Congressional Action to Limit Antibiotic Use in Animal Agriculture
Post Your Comments:
Related Image:
Antibiotic Combo Fights Resistant TB
(Date:10/13/2015)... , ... October 13, 2015 , ... ... review of Anik Singal's newly launched "Publish Academy" training course . Singal's ... business opened for enrollment today, and marketers around the Internet are weighing in ...
(Date:10/13/2015)... ... October 13, 2015 , ... T-System and Centegra ... than 59,000 emergency department visits per year, today announced the successful and rapid ... improve clinical, operational and financial outcomes. , In less than four ...
(Date:10/13/2015)... ... , ... Local Gold’s Gym franchise owner, Bryce Berry, received the Visionary of ... owns and operates Gold's Gym Cheyenne in Cheyenne, Wyoming, received the award ... States. A brand leader in global fitness, Gold’s Gyms are located worldwide. Every fitness ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... Affinity have developed valuable new strategies for enrolling and serving insurance consumers who ... to obtain health insurance and pay monthly premiums. In “Health Plan Engagement Strategies: ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... team: Debbie Vereb has been named the organization’s Executive Vice President of ... have been hired to key leadership roles in the company. , Debbie Vereb’s ...
Breaking Medicine News(10 mins):
(Date:10/12/2015)... MENLO PARK, Calif. , Oct. 12, ... of R&D and Chief Scientific Officer of ... leading biotechnology company in the emerging field ... BioPharma Dealmakers webcast, sponsored in part by ... medicine. Dr. Lebkowski will discuss the progress ...
(Date:10/12/2015)... 12, 2015 The global infertility treatment ... million by 2020 from USD 1,822.32 million in ... and 2020. By product, the market includes antivibration ... systems, micromanipulator systems, ovum aspiration pumps, sperm analyzer ... market is segmented into in vitro fertilization, artificial ...
(Date:10/12/2015)... -- Elbit Imaging Ltd. ("EI" or the "Company") ... of directors approved a program to repurchase up to NIS ... Notes and Series I Notes, which are traded on the ... Company will have a significant preference to the purchase Series ... time in the open market on the Tel Aviv Stock ...
Breaking Medicine Technology: